Expert Review of Endocrinology & Metabolism最新文献_第2页

Beyond normalization: rethinking optimal prolactin levels in prolactinoma management. 超越正常化：重新思考最佳催乳素水平在催乳素瘤的管理。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-07-01 Epub Date: 2026-05-26 DOI: 10.1080/17446651.2026.2679517

Antoni Puzio, Monika Hylinska, Oliwer Kapała, Maciej Owecki

{"title":"Beyond normalization: rethinking optimal prolactin levels in prolactinoma management.","authors":"Antoni Puzio, Monika Hylinska, Oliwer Kapała, Maciej Owecki","doi":"10.1080/17446651.2026.2679517","DOIUrl":"10.1080/17446651.2026.2679517","url":null,"abstract":"Introduction: Prolactinoma, the most common functioning pituitary tumor, poses ongoing challenges due to variable clinical presentation, treatment resistance, and high recurrence rates. While normalization of prolactin (PRL) is a primary therapeutic goal, increasing evidence suggests that both insufficient and excessive PRL suppression may influence long-term outcomes.Areas covered: A narrative literature search of PubMed, Embase, Scopus, Cochrane, and Web of Science was conducted without date restrictions. The review primarily included English-language studies published from 2015 through February 2026, while selected earlier studies were included when they provided essential background context. This review synthesizes current evidence on optimal prolactin levels in prolactinoma management, based on literature from clinical and observational studies. We examine the role of PRL dynamics as a marker of treatment response across pharmacological and surgical approaches. Particular attention is given to predictors of remission, recurrence after dopamine agonist withdrawal, and the clinical implications of both hyper- and hypoprolactinemia.Expert opinion: Lower prolactin levels are associated with improved clinical outcomes; however, excessively low levels do not necessarily indicate optimal therapy and may carry overlooked risks. Early PRL trends reflect tumor response, underscoring the need to define optimal targets for individualized prolactinoma management.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"291-305"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148028766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is metformin therapy limiting the benefits of exercise? 二甲双胍治疗是否限制了运动的益处？

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-07-01 Epub Date: 2026-05-12 DOI: 10.1080/17446651.2026.2672989

Steven K Malin

引用次数: 0

Surgical considerations for adult Graves' disease: a narrative review of indications, perioperative challenges and postoperative outcomes. 成人格雷夫斯病的手术考虑：适应症、围手术期挑战和术后结果的叙述性回顾。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-07-01 Epub Date: 2026-05-21 DOI: 10.1080/17446651.2026.2676876

Luigi Bartalena, Daniela Gallo, Eliana Piantanida, Maria Laura Tanda

{"title":"Surgical considerations for adult Graves' disease: a narrative review of indications, perioperative challenges and postoperative outcomes.","authors":"Luigi Bartalena, Daniela Gallo, Eliana Piantanida, Maria Laura Tanda","doi":"10.1080/17446651.2026.2676876","DOIUrl":"10.1080/17446651.2026.2676876","url":null,"abstract":"Introduction: Graves' disease (GD) is a systemic autoimmune disorder, ultimately caused by autoantibodies stimulating the TSH receptor (TSHR-Ab) on thyroid follicular cells. Novel targeted therapies are under investigation, but treatment of GD still relies on antithyroid drugs (ATDs), radioactive iodine, or thyroidectomy.Areas covered: Narrative review of original articles, randomized clinical trials, systematic reviews and meta-analyses, guidelines on PubMed from inception to March 2026, using the following terms: GD, management of GD, thyroidectomy, hypoparathyroidism, hypocalcemia, recurrent laryngeal nerve injury, hematoma, near-infrared autofluorescence, indocyanine green angiography, Graves' orbitopathy, thyroid eye disease.Expert opinion: Thyroidectomy is the least common treatment for GD. However, it effectively eradicates hyperthyroidism, if all thyroid tissue is removed. Preoperative preparation includes ATD treatment to restore euthyroidism whenever possible, iodine solution (controversial in patients rendered euthyroid prior to surgery), and vitamin D (with or without calcium), if deficient. In patients with risk factors for cardiovascular (CV) complications, thyroidectomy may prevent the CV risk associated with unstable/severe hyperthyroidism. Thyroidectomy is safe in the hands of skilled, high-volume surgeons, with a low incidence of the main complications, i.e. hypoparathyroidism, recurrent laryngeal nerve injury, and hematoma.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"271-289"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147987110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New guidelines for premature ovarian insufficiency: a step forward or more hurdles? 卵巢功能不全的新指南：向前迈进一步还是更多障碍？

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2026-05-01 Epub Date: 2026-04-23 DOI: 10.1080/17446651.2026.2662444

Arianna Daneri, Matteo Lambertini

引用次数: 0

The intersection of education and health: schools as a catalyst for childhood obesity prevention. 教育与健康的交集：学校作为儿童肥胖预防的催化剂。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-05-01 Epub Date: 2026-03-20 DOI: 10.1080/17446651.2026.2647962

Thomas M Barber, Elizabeth V Niven, Peter Tymms

{"title":"The intersection of education and health: schools as a catalyst for childhood obesity prevention.","authors":"Thomas M Barber, Elizabeth V Niven, Peter Tymms","doi":"10.1080/17446651.2026.2647962","DOIUrl":"10.1080/17446651.2026.2647962","url":null,"abstract":"Introduction: The traditional school environment places emphasis on educational outcomes. There is great potential to build on existing work to re-design a school of the future that conflates both educational and healthcare provision for our children. This includes provision for the burgeoning global problem of childhood obesity and its sequelae. Through addressing the health, wellbeing and educational needs of our children, the future school should optimize health, happiness and success in adulthood.Areas covered: We provide a template for a re-designed future school that optimizes the educational, health and wellbeing needs of our children (including the prevention of excessive weight gain) through changes to the physical environment, routine, food, cultural, and learning environments. Pubmed searches: published data on childhood obesity and its association with adulthood obesity, and existing innovations within schools, including those to improve physical activity and healthy eating.Expert opinion: Children experience the world (and school) holistically. We need to align our re-design of schools accordingly. Given the links between health, wellbeing and educational attainment in children, we argue that the future school should ultimately contribute meaningfully toward a healthier, happier and more productive society.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"181-193"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147485163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Hellenic study on insulin technique and administration (HELITA). 希腊胰岛素技术与给药研究（HELITA）。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-05-01 Epub Date: 2026-04-20 DOI: 10.1080/17446651.2026.2663053

Anastasios Kaisidis, Athanasia Papazafiropoulou, Eleni Papadokostaki, Malamatenia Koymaki, Theocharis Koufakis, Nikolaos Papanas, Kyriakos Kazakos

{"title":"The Hellenic study on insulin technique and administration (HELITA).","authors":"Anastasios Kaisidis, Athanasia Papazafiropoulou, Eleni Papadokostaki, Malamatenia Koymaki, Theocharis Koufakis, Nikolaos Papanas, Kyriakos Kazakos","doi":"10.1080/17446651.2026.2663053","DOIUrl":"10.1080/17446651.2026.2663053","url":null,"abstract":"Background: The Hellenic study on Insulin Technique and Administration (HELITA) is a national questionnaire survey in Greece aiming to assess insulin administration practices among people with diabetes.Research design and methods: The study enrolled 701 insulin-treated adults with type 1 and type 2 diabetes recruited from 40 diabetes care settings. Participants completed a structured questionnaire on insulin administration practices and underwent physical assessment of all injection sites by diabetes educators.Results: Most participants (57.6%) reused insulin pen needles, while 38.9% did not rotate injection sites. Incorrect insulin dose titration was reported by 17.3%, 39.1% used long needles (8 mm), and 30.1% stored insulin incorrectly after first use. Notably, 41.1% had never had their injection sites inspected by healthcare professionals, and lipohypertrophy was diagnosed in 55.1%. Multivariate analysis showed that missed insulin doses (Odds Ratio: 1.73, 95% Confidence Interval: 1.14-2.62, p = 0.01) and lipohypertrophy were associated with poorer glycemic control. Increased risk of lipohypertrophy was observed among participants who did not rotate injection sites, reused needles, or lacked systematic education on insulin administration.Conclusions: Continuous education on insulin injection practices may contribute to improving glycemic control and reducing the risk of lipohypertrophy.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"231-243"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147728520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Osteoporosis in chronic kidney disease: diagnostic dilemmas and therapeutic controversies. 慢性肾脏疾病骨质疏松：诊断困境和治疗争议。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-05-01 Epub Date: 2026-03-22 DOI: 10.1080/17446651.2026.2646161

Sukanya Sakthivel, Marie Houmaa Vrist, Bente Langdahl, Hanne Skou Jørgensen

{"title":"Osteoporosis in chronic kidney disease: diagnostic dilemmas and therapeutic controversies.","authors":"Sukanya Sakthivel, Marie Houmaa Vrist, Bente Langdahl, Hanne Skou Jørgensen","doi":"10.1080/17446651.2026.2646161","DOIUrl":"10.1080/17446651.2026.2646161","url":null,"abstract":"Introduction: Fracture risk is substantially increased in chronic kidney disease (CKD) and rises with declining kidney function. Skeletal fragility in CKD results from reduced bone mass, altered bone microarchitecture, and disturbances in mineral and endocrine regulation of bone turnover, leading to high morbidity and mortality.Areas covered: This review summarizes recent data on fracture incidence across CKD stages and discusses current diagnostic challenges, including the role and limitations of fracture risk prediction tools, dual-energy X-ray absorptiometry, and biochemical markers of mineral metabolism and bone turnover. The contribution of advanced imaging techniques to microarchitectural assessment is also addressed. Current guideline-based approaches are reviewed, alongside therapeutic considerations and the limited evidence supporting osteoporosis treatments in advanced CKD. A literature search was performed in Pubmed restricted to clinical studies published from 2015 through 2025 for a contemporary update on the topic. Osteoporosis after kidney transplantation was not included.Expert opinion: In the absence of evidence-based treatment protocols for CKD-associated osteoporosis, fracture prevention should rely on pragmatic individualized risk assessment. Optimization of mineral metabolism and cautious use of bone-targeting therapies in high-risk patients are key components of management strategy. Future studies should prioritize CKD-specific fracture outcomes and validated diagnostic strategies to guide treatment decisions.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"205-216"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147498038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The evaluation of plozasiran for the treatment of familial chylomicronemia syndrome. 普罗扎西兰治疗家族性乳糜微粒血症综合征的疗效评价。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-05-01 Epub Date: 2026-03-20 DOI: 10.1080/17446651.2026.2646166

Shyann Hang, Robert A Hegele

{"title":"The evaluation of plozasiran for the treatment of familial chylomicronemia syndrome.","authors":"Shyann Hang, Robert A Hegele","doi":"10.1080/17446651.2026.2646166","DOIUrl":"10.1080/17446651.2026.2646166","url":null,"abstract":"Introduction: Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder marked by severe hypertriglyceridemia and characteristic clinical manifestations, particularly acute pancreatitis. Conventional triglyceride-lowering therapy is largely ineffective. Apolipoprotein (apo) C-III has emerged as a key therapeutic target to lower triglycerides in FCS.Areas covered: This review compares FCS with more common multifactorial chylomicronemia. We searched PubMed for all English language literature focusing on the search terms 'chylomicronemia,' 'hypertriglyceridemia,' 'APOC3 inhibition,' 'plozasiran,' 'olezarsen,' and 'volanesorsen.' We outline traditional management strategies and their limited role in FCS and explore non-traditional therapies including orlistat, lomitapide, inhibitors of angiopoietin like protein 3 (ANGPTL3), and analogues of fibroblast growth factor 21 (FGF21). The primary focus is on RNA-based gene silencing therapeutics that target apo C-III, particularly the small interfering RNA plozasiran and the allele specific oligonucleotides volanesorsen and olezarsen, highlighting key differences in efficacy and tolerability.Expert opinion: In a phase 3 trial of plozasiran, at 10 months, median placebo-adjusted reductions in apo C-III were approximately -90%, while TG levels were reduced up to -59%. Thus, plozasiran and alternative RNA-based therapeutics directed against APOC3 represent transformational therapies for patients with FCS and related phenotypes characterized by severe recalcitrant hypertriglyceridemia.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"195-204"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147485124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of pharmacotherapies for obesity with sleeve gastrectomy: a network meta-analysis and systematic review. 肥胖症药物治疗与袖式胃切除术的比较：网络荟萃分析和系统评价。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-05-01 Epub Date: 2026-04-12 DOI: 10.1080/17446651.2026.2656247

Zachary Omeh, Tahira Khan, Olalekan Uthman, Thomas M Barber

{"title":"Comparison of pharmacotherapies for obesity with sleeve gastrectomy: a network meta-analysis and systematic review.","authors":"Zachary Omeh, Tahira Khan, Olalekan Uthman, Thomas M Barber","doi":"10.1080/17446651.2026.2656247","DOIUrl":"10.1080/17446651.2026.2656247","url":null,"abstract":"Introduction: Tirzepatide, a glucagon-like peptide-1 receptor agonist (GLP1RA) and glucose-dependent insulinotropic-peptide (GIP), has shown efficacy regarding weight-loss.Methods: Systematic review and network meta-analysis of randomized controlled trials. MEDLINE, EMBASE, and Cochrane CENTRAL databases were searched between 2014 and 2024 for trials comparing sleeve gastrectomy (SG), Tirzepatide and other pharmacotherapies to control or each other. Eligible studies: adults with obesity and weight loss outcomes ≥24 weeks. Primary outcome: percentage change total body weight. Secondary outcomes included adverse events. Pairwise and network meta-analyses were performed. Interventions ranked by: P-score, mean difference (MD), 95% confidence intervals (CI).Results: Data from 23 trials (14,293 participants) were analyzed. SG (MD 21.1% TWL, 95% CI 14.2% to 28.0%) and Tirzepatide 10 or 15 mg (MD 21.3% TWL, 95% CI 17.3% to 25.2%) demonstrated statistically equivalent weight-loss efficacy (P-score: 0.84) and had the most favorable effectiveness profiles. Semaglutide 2.4 mg (MD 12.7% TWL) and Liraglutide 3.0 mg (MD 5.1% TWL) showed moderate efficacy, whilst Orlistat showed minimal effect (MD 2.7% TWL, 95% CI -4.2% to 9.6%). Network meta-analysis of adverse events demonstrated that Semaglutide 2.4 mg and Orlistat had the most favorable safety profiles amongst pharmacotherapies.Conclusions: Tirzepatide 10 mg and 15 mg is equivalent to SG regarding weight-loss efficacy.Registration: This paper was registered with PROSPERO (ID: CRD420251016726). Due to institutional academic requirements and checks, registration was completed after the review began, however the review protocol (supplement material S1) was developed prior to the review, provided by the authors, and thoroughly adhered to by the authors.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"217-229"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147671845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring actions of glucagon-like peptide-1 receptor agonists (GLP-1RAs) beyond glucose and obesity control: bone health and osteoporosis. 探索胰高血糖素样肽-1受体激动剂（GLP-1RAs）在血糖和肥胖控制之外的作用：骨骼健康和骨质疏松症。

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2026-05-01 Epub Date: 2026-04-07 DOI: 10.1080/17446651.2026.2652305

Athanasios Kasotas, Maria Apostolopoulou

引用次数: 0